TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protara Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.33+0.01 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $142.15M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.16 (−57.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $142.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.88
- Dividend yield
- –
- Free cash flow yield
- -39.72%
Fundamentals
- Net income
- -$70.02M
- EPS, diluted
- -$1.36
- Free cash flow
- -$56.46M
- Book value per share
- $2.64
- Diluted shares
- 61M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$76.79M
Net income
-$70.02M
EPS, diluted
-$1.36
Free cash flow
–
Reported periodTrailing twelve months